157 related articles for article (PubMed ID: 8014665)
21. Glucose transport across the blood-brain barrier in normal human subjects and patients with cerebral tumours studied using [11C]3-O-methyl-D-glucose and positron emission tomography.
Brooks DJ; Beaney RP; Lammertsma AA; Herold S; Turton DR; Luthra SK; Frackowiak RS; Thomas DG; Marshall J; Jones T
J Cereb Blood Flow Metab; 1986 Apr; 6(2):230-9. PubMed ID: 3007547
[TBL] [Abstract][Full Text] [Related]
22. Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors.
Janus TJ; Kim EE; Tilbury R; Bruner JM; Yung WK
Ann Neurol; 1993 May; 33(5):540-8. PubMed ID: 8498831
[TBL] [Abstract][Full Text] [Related]
23. FDG-PET in pediatric posterior fossa brain tumors.
Hoffman JM; Hanson MW; Friedman HS; Hockenberger BM; Oakes WJ; Halperin EC; Coleman RE
J Comput Assist Tomogr; 1992; 16(1):62-8. PubMed ID: 1729308
[TBL] [Abstract][Full Text] [Related]
24. [18F]fluorodeoxyglucose uptake in tumors: kinetic vs. steady-state methods with reference to plasma insulin.
Minn H; Leskinen-Kallio S; Lindholm P; Bergman J; Ruotsalainen U; Teräs M; Haaparanta M
J Comput Assist Tomogr; 1993; 17(1):115-23. PubMed ID: 8419418
[TBL] [Abstract][Full Text] [Related]
25. Uncoupling of hexose transport and phosphorylation in human gliomas demonstrated by PET.
Herholz K; Ziffling P; Staffen W; Pawlik G; Wagner R; Wienhard K; Heiss WD
Eur J Cancer Clin Oncol; 1988 Jul; 24(7):1139-50. PubMed ID: 3262062
[TBL] [Abstract][Full Text] [Related]
26. [PET assessment of myocardial viability with glucose loading and fasting FDG images].
Niwayama H; Yoshida K; Kagaya A; Himi T; Masuda Y; Inagaki Y; Ito Y; Uematsu S; Imazeki K; Arimizu N
Kaku Igaku; 1990 Mar; 27(3):285-8. PubMed ID: 2352373
[TBL] [Abstract][Full Text] [Related]
27. Modification of glucose metabolism in brain tumors by using cervical spinal cord stimulation.
Clavo B; Robaina F; Montz R; Domper M; Carames MA; Morera J; Pinar B; Hernandez MA; Santullano V; Carreras JL
J Neurosurg; 2006 Apr; 104(4):537-41. PubMed ID: 16619657
[TBL] [Abstract][Full Text] [Related]
28. Glucose consumption and rate constants for 18F-fluorodeoxyglucose in human gliomas.
Ishikawa M; Kikuchi H; Nagata I; Yamagata S; Taki W; Yonekura Y; Nishizawa S; Iwasaki Y; Mukai T
Neurol Med Chir (Tokyo); 1990 Jun; 30(6):377-81. PubMed ID: 1700316
[TBL] [Abstract][Full Text] [Related]
29. [In vivo measurements of regional cerebral hemocirculation and metabolism in gliomas using 15O and 18F-fluorodeoxyglucose positron emission tomography].
Mineura K; Yasuda T; Kowada M; Shishido F; Ogawa T; Uemura K
No To Shinkei; 1986 Apr; 38(4):337-44. PubMed ID: 3013262
[TBL] [Abstract][Full Text] [Related]
30. Impact of fluorodeoxyglucose positron emission tomography on the clinical management of patients with glioma.
Deshmukh A; Scott JA; Palmer EL; Hochberg FH; Gruber M; Fischman AJ
Clin Nucl Med; 1996 Sep; 21(9):720-5. PubMed ID: 8879874
[TBL] [Abstract][Full Text] [Related]
31. Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET.
Kahn D; Follett KA; Bushnell DL; Nathan MA; Piper JG; Madsen M; Kirchner PT
AJR Am J Roentgenol; 1994 Dec; 163(6):1459-65. PubMed ID: 7992747
[TBL] [Abstract][Full Text] [Related]
32. Brain imaging of glucose utilization in cerebral tumors.
Di Chiro G
Res Publ Assoc Res Nerv Ment Dis; 1985; 63():185-97. PubMed ID: 3875134
[No Abstract] [Full Text] [Related]
33. Clinical value of PET with 18F-fluorodeoxyglucose and L-methyl-11C-methionine for diagnosis of recurrent brain tumor and radiation injury.
Ogawa T; Kanno I; Shishido F; Inugami A; Higano S; Fujita H; Murakami M; Uemura K; Yasui N; Mineura K
Acta Radiol; 1991 May; 32(3):197-202. PubMed ID: 2064862
[TBL] [Abstract][Full Text] [Related]
34. FDG-PET as a prognostic indicator in radiochemotherapy of glioblastoma.
Hölzer T; Herholz K; Jeske J; Heiss WD
J Comput Assist Tomogr; 1993; 17(5):681-7. PubMed ID: 8370819
[TBL] [Abstract][Full Text] [Related]
35. Enhanced detectability of recurrent brain tumor using glucose-loading F-18 FDG PET.
Seo YS; Chung TW; Kim IY; Bom HS; Min JJ
Clin Nucl Med; 2008 Jan; 33(1):32-3. PubMed ID: 18097254
[TBL] [Abstract][Full Text] [Related]
36. Decreased cerebral glucose metabolism in patients with brain tumors: an effect of corticosteroids.
Fulham MJ; Brunetti A; Aloj L; Raman R; Dwyer AJ; Di Chiro G
J Neurosurg; 1995 Oct; 83(4):657-64. PubMed ID: 7674016
[TBL] [Abstract][Full Text] [Related]
37. Positron emission tomography of fluorine-18-deoxyglucose and image-guided phosphorus-31 magnetic resonance spectroscopy in brain tumors.
Heiss WD; Heindel W; Herholz K; Rudolf J; Bunke J; Jeske J; Friedmann G
J Nucl Med; 1990 Mar; 31(3):302-10. PubMed ID: 2308001
[TBL] [Abstract][Full Text] [Related]
38. Prediction of survival in glioma patients by means of positron emission tomography.
Patronas NJ; Di Chiro G; Kufta C; Bairamian D; Kornblith PL; Simon R; Larson SM
J Neurosurg; 1985 Jun; 62(6):816-22. PubMed ID: 2987440
[TBL] [Abstract][Full Text] [Related]
39. Serial FDG-PET studies in the prediction of survival in patients with primary brain tumors.
Schifter T; Hoffman JM; Hanson MW; Boyko OB; Beam C; Paine S; Schold SC; Burger PC; Coleman RE
J Comput Assist Tomogr; 1993; 17(4):509-61. PubMed ID: 8392523
[TBL] [Abstract][Full Text] [Related]
40. [Regional cerebral glucose metabolism associated with ataxic gait--an FDG-PET activation study in patients with olivopontocerebellar atrophy].
Mishina M; Senda M; Ohyama M; Ishii K; Kitamura S; Terashi A
Rinsho Shinkeigaku; 1995 Nov; 35(11):1199-204. PubMed ID: 8720328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
